Initiation of Phase III Clinical Trials. Licensee will notify GenuPro in writing upon its first initiation of a Phase III Clinical Study in the Field involving a CTM Product within fourteen (14) days of such initiation. Within thirty (30) days of such initiation, Licensee will pay GenuPro a one-time milestone payment of [*].
Appears in 6 contracts
Samples: License Agreement (Furiex Pharmaceuticals, Inc.), License Agreement (Furiex Pharmaceuticals, Inc.), License Agreement (Furiex Pharmaceuticals, Inc.)
